UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.237-250

2017

Volltextzugriff (PDF)

Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Molecular pharmacology, 2008-12, Vol.74 (6), p.1722-1728

2008

Volltextzugriff (PDF)

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

Molecules (Basel, Switzerland), 2018-08, Vol.23 (8), p.2041

2018

Volltextzugriff (PDF)

The use of dexrazoxane for the prevention of anthracycline extravasation injury

Expert opinion on investigational drugs, 2008-02, Vol.17 (2), p.217-223

Hasinoff, Brian B

2008

Volltextzugriff (PDF)

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

Cardiovascular toxicology, 2010-03, Vol.10 (1), p.1-8

2010

Volltextzugriff (PDF)

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Cardiovascular toxicology, 2020-06, Vol.20 (3), p.312-320

2020

Volltextzugriff (PDF)

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

Cardiovascular toxicology, 2020-08, Vol.20 (4), p.380-389

2020

Volltextzugriff (PDF)

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

The Journal of pharmacology and experimental therapeutics, 2016-02, Vol.356 (2), p.397

2016

Volltextzugriff (PDF)

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.297-306

2017

Volltextzugriff (PDF)

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

Cardiovascular toxicology, 2018-12, Vol.18 (6), p.557-568

2018

Volltextzugriff (PDF)

Abstract 3060: Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib and carfilzomib

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3060-3060

2016

Volltextzugriff (PDF)

Total Synthesis of Isoprekinamycin: Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells

Organic letters, 2007-07, Vol.9 (15), p.2915-2918

2007

Volltextzugriff (PDF)

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

Drug metabolism and disposition, 2008-09, Vol.36 (9), p.1780-1785

2008

Volltextzugriff (PDF)

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

Drug metabolism and disposition, 2005-09, Vol.33 (9), p.1367-1372

2005

Volltextzugriff (PDF)

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

Molecular pharmacology, 2003-09, Vol.64 (3), p.670-678

2003

Volltextzugriff (PDF)

Dexrazoxane use in the prevention of anthracycline extravasation injury

Future oncology (London, England), 2006-02, Vol.2 (1), p.15-20

Hasinoff, Brian B

2006

Volltextzugriff (PDF)

Expression of a stress‐induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress

The Plant journal : for cell and molecular biology, 2003-09, Vol.35 (6), p.763-770

2003

Volltextzugriff (PDF)

Class-1 hemoglobins, nitrate and NO levels in anoxic maize cell-suspension cultures

Planta, 2004-05, Vol.219 (1), p.66-72

2004

Volltextzugriff (PDF)

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

Cardiovascular toxicology, 2007-06, Vol.7 (2), p.140-144

2007

Volltextzugriff (PDF)

Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay

Free radical research, 2008-05, Vol.42 (5), p.435-441

2008

Volltextzugriff (PDF)

Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood

Drug metabolism and disposition, 2005-06, Vol.33 (6), p.719

2005

Volltextzugriff (PDF)

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

Cardiovascular toxicology, 2003, Vol.3 (2), p.89-100

2003

Volltextzugriff (PDF)

The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin

Cardiovascular toxicology, 2013-03, Vol.13 (1), p.33-47

2013

Volltextzugriff (PDF)

Abstract 1878: Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib, carfilzomib, ixazomib, oprozomib, and delanzomib

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1878-1878

Hasinoff, Brian B.

2018

Volltextzugriff (PDF)

Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187)

Drug metabolism and disposition, 2002-12, Vol.30 (12), p.1431-1435

2002

Volltextzugriff (PDF)

1 – 25 von 123

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(123)

Sprache

Englisch
(123)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

The use of dexrazoxane for the prevention of anthracycline extravasation injury

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

Abstract 3060: Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib and carfilzomib

Total Synthesis of Isoprekinamycin: Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

Dexrazoxane use in the prevention of anthracycline extravasation injury

Expression of a stress‐induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress

Class-1 hemoglobins, nitrate and NO levels in anoxic maize cell-suspension cultures

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay

Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin

Abstract 1878: Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib, carfilzomib, ixazomib, oprozomib, and delanzomib

Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187)

Aktive Filter

Suchergebnisse filtern